GlassScriptPhysician profile
Matthew Culbreth
NPI 1790352722
$6,843.25
in general payments reported to CMS, 2019-2025
17 companies · $2,082 in 2025
The $2,082 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $735 · 2022: $1,135 · 2023: $1,370 · 2024: $1,522 · 2025: $2,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,704 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,703.92 |
| Education | $269.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,525.95 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $1,218.48 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $968.08 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $773.94 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $493.38 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $441.24 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $431.01 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $383.69 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Indivior INC. | $182.25 | 2021-2025 | Perseris, Sublocade |
| Noven Therapeutics, LLC | $93.70 | 2023-2025 | Secuado |
| E.R. Squibb & Sons, L.L.C. | $81.85 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $58.39 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $46.30 | 2025 | Fanapt |
| Acadia Pharmaceuticals INC | $39.63 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.67 | 2023-2025 | Trintellix |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioxcel Therapeutics, INC. | $36.74 | 2023 | Igalmi |
| Idorsia Pharmaceuticals US INC | $30.95 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Culbreth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.